CN120344665A - 具有受控缔合的多肽 - Google Patents

具有受控缔合的多肽

Info

Publication number
CN120344665A
CN120344665A CN202380085639.1A CN202380085639A CN120344665A CN 120344665 A CN120344665 A CN 120344665A CN 202380085639 A CN202380085639 A CN 202380085639A CN 120344665 A CN120344665 A CN 120344665A
Authority
CN
China
Prior art keywords
polypeptide
region
modification
nucleic acid
modifications
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380085639.1A
Other languages
English (en)
Chinese (zh)
Inventor
古贺光
清水骏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of CN120344665A publication Critical patent/CN120344665A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202380085639.1A 2022-12-27 2023-12-27 具有受控缔合的多肽 Pending CN120344665A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022210580 2022-12-27
JP2022-210580 2022-12-27
PCT/JP2023/046857 WO2024143442A1 (ja) 2022-12-27 2023-12-27 会合が制御されたポリペプチド

Publications (1)

Publication Number Publication Date
CN120344665A true CN120344665A (zh) 2025-07-18

Family

ID=91717763

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380085639.1A Pending CN120344665A (zh) 2022-12-27 2023-12-27 具有受控缔合的多肽

Country Status (4)

Country Link
EP (1) EP4644548A1 (https=)
JP (1) JPWO2024143442A1 (https=)
CN (1) CN120344665A (https=)
WO (1) WO2024143442A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025228542A1 (en) * 2024-05-03 2025-11-06 Genmab B.V. Method for co-expression of a plurality of antibodies

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
AU687010B2 (en) 1992-07-17 1998-02-19 Dana-Farber Cancer Institute Method of intracellular binding of target molecules
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
US20030104402A1 (en) 2001-01-23 2003-06-05 University Of Rochester Methods of producing or identifying intrabodies in eukaryotic cells
WO2003077945A1 (en) 2002-03-14 2003-09-25 Medical Research Council Intracellular antibodies
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AU2006232287B2 (en) * 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
ES2758994T3 (es) * 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
US9248181B2 (en) * 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
CN102851338A (zh) 2012-07-25 2013-01-02 苏州康宁杰瑞生物科技有限公司 利用电荷排斥作用制备同二聚体蛋白混合物的方法
CN109475627B (zh) 2016-05-26 2023-01-06 齐鲁普吉湾生物治疗公司 抗体混合物
TWI874341B (zh) * 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
AR125344A1 (es) 2021-04-15 2023-07-05 Chugai Pharmaceutical Co Ltd Anticuerpo anti-c1s

Also Published As

Publication number Publication date
JPWO2024143442A1 (https=) 2024-07-04
WO2024143442A1 (ja) 2024-07-04
EP4644548A1 (en) 2025-11-05

Similar Documents

Publication Publication Date Title
TWI818387B (zh) 結合cd3之抗體
JP7085666B2 (ja) Ｄｌｌ３標的多重特異性抗原結合分子およびその使用
JP6463522B2 (ja) Ａｓｇｐｒ抗体およびその使用
TW202204410A (zh) 免疫活化多特異性抗原結合分子及其用途
CN116888153A (zh) 与γ-δT细胞受体结合的抗体
CN116925215A (zh) 抗血清白蛋白纳米抗体及其衍生物
CN113271972A (zh) 用于替代IVIG的多聚体杂交Fc蛋白
JP2026010057A (ja) 部位特異的Ｎｏｔｃｈ活性化分子およびその使用
CN117003872A (zh) 含有突变轻链可变区骨架的单链抗体片段
TWI911155B (zh) 藉由多肽鏈交換活化之治療性多特異性多肽
CN120344665A (zh) 具有受控缔合的多肽
CN119698294A (zh) 结合γ-δT细胞受体的变体抗体
HK40121051A (zh) 具有受控缔合的多肽
CN118369349A (zh) 与cd3和plap结合的抗体
EP4631975A1 (en) Fusion comprising anti-tau antibody and peptide and use thereof
HK40095327A (zh) 含有突变轻链可变区骨架的单链抗体片段
TW202606763A (zh) 特異性結合經修飾之寡核苷酸的抗體
CA3276286A1 (en) Fusion comprising anti-tau antibody and peptide and use thereof
WO2024097938A1 (en) Compositions and methods for increasing transport into the brain
TW202535927A (zh) 與ｃｅａｃａｍ５結合之抗體
HK40110726A (zh) 包含基於mhc蛋白的异源二聚体的双特异性抗体
TW202612736A (zh) Dll3靶向之多特異性抗原結合分子及其用途
HK40106996A (zh) 与cd3结合的抗体
HK40129971A (zh) 用於产生免疫球蛋白样分子的方法和手段
HK40091593A (zh) 与cd3和folr1结合的抗体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40121051

Country of ref document: HK